JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Hologic Inc

Затворен

СекторЗдравеопазване

74.02 0.16

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

73.84

Максимум

74.1

Ключови измерители

By Trading Economics

Приходи

212M

195M

Продажби

19M

1B

P/E

Средно за сектора

28.98

37.461

EPS

1.08

Марж на печалбата

19.037

Служители

7,063

EBITDA

341M

334M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+5.42% upside

Дивиденти

By Dow Jones

Следващи печалби

3.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.3B

16B

Предишно отваряне

73.86

Предишно затваряне

74.02

Настроения в новините

By Acuity

25%

75%

51 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Hologic Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.10.2025 г., 13:20 ч. UTC

Придобивния, сливания и поглъщания

Blackstone, TPG to Buy Hologic for Up to $18.3 Billion

27.05.2025 г., 18:46 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Hologic Shares Up Following Report of Buyout Offer From TPG, Blackstone

21.10.2025 г., 16:36 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Hologic Seen as Prime Take-Private Candidate -- Market Talk

21.10.2025 г., 13:05 ч. UTC

Придобивния, сливания и поглъщания

Blackstone, TPG to Buy Hologic for Up to $18.3B

21.10.2025 г., 12:50 ч. UTC

Придобивния, сливания и поглъщания

Hologic Plans to File Form 10-K for Fiscal 2025 With the SEC in Late Nov >HOLX

21.10.2025 г., 12:49 ч. UTC

Придобивния, сливания и поглъщания

Hologic Does Not Intend to Provide Fincl Guidance for FY26 in Upcoming 4Q Results Release

21.10.2025 г., 12:48 ч. UTC

Придобивния, сливания и поглъщания

Hologic Merger Agreement Includes a 45-Day 'Go-Shop' Period >HOLX

21.10.2025 г., 12:48 ч. UTC

Придобивния, сливания и поглъщания

Hologic Will Continue to Operate Under the Hologic Name and Brand >HOLX

21.10.2025 г., 12:48 ч. UTC

Придобивния, сливания и поглъщания

Hologic Will Maintain Its Headquarters in Marlborough, Massachusetts >HOLX

21.10.2025 г., 12:47 ч. UTC

Придобивния, сливания и поглъщания

Blackstone's Private Equity Strategy for Individual Investors Is Also Expected to Invest as Part of Transaction

21.10.2025 г., 12:46 ч. UTC

Придобивния, сливания и поглъщания

Blackstone and TPG Secured Committed Financing From Citi, Bank of Amer, Barclays, Royal Bank of Canada and SMBC

21.10.2025 г., 12:46 ч. UTC

Придобивния, сливания и поглъщания

Blackstone and TPG Have Secured Committed Financing for the Transaction >HOLX

21.10.2025 г., 12:45 ч. UTC

Придобивния, сливания и поглъщания

Hologic: Transaction Includes Significant Minority Investments From Subsidiary of Abu Dhabi Investment Authority and an Affil of GIC >HOLX

21.10.2025 г., 12:45 ч. UTC

Придобивния, сливания и поглъщания

Hologic: Purchase Price Represents Premium of About 46% to Closing Price on May 23 >HOLX

21.10.2025 г., 12:45 ч. UTC

Придобивния, сливания и поглъщания

Hologic: Non-tradable CVR Would Be Issued to Holders at Closing and Paid Following Achievement of Certain Global Rev Goals for Breast Health Business in FY26, FY27

21.10.2025 г., 12:44 ч. UTC

Придобивния, сливания и поглъщания

Blackstone and TPG Will Acquire Hologic Shrs for $76/Shr in Cash Plus Non-Tradable CVR to Get Up to $3/Shr for Total of Up to $79/Shr in Cash >HOLX

21.10.2025 г., 12:42 ч. UTC

Придобивния, сливания и поглъщания

Hologic: Transaction Will Help Strengthen Leadership in Women's Health and Accelerate Growth >HOLX

21.10.2025 г., 12:42 ч. UTC

Придобивния, сливания и поглъщания

Hologic to Be Acquired by Funds Managed by Blackstone Deal and TPG in Deal With Enterprise Value of Up to $18.3 B >BX HOLX

27.05.2025 г., 20:07 ч. UTC

Придобивния, сливания и поглъщания

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27.05.2025 г., 19:06 ч. UTC

Придобивния, сливания и поглъщания

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27.05.2025 г., 18:26 ч. UTC

Придобивния, сливания и поглъщания

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 19%. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Hologic Inc Прогноза

Ценова цел

By TipRanks

5.42% нагоре

12-месечна прогноза

Среден 78 USD  5.42%

Висок 94 USD

Нисък 69 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Hologic Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

13 ratings

3

Купи

10

Задържане

0

Продай

Техническа оценка

By Trading Central

52.69 / 58.605Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

51 / 371 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Hologic Inc

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat